Evidence map›Paper›PMID 36810454›Full record

ArticleEpidemiologia (Basel, Switzerland)2023

ABO Blood Groups and Incidence of COVID-19 in the Mass Gathering Events in Borriana (Spain), March 2020: A Retrospective Cohort Study.

Salvador Domènech-Montoliu, Joan Puig-Barberà, Olga Guerra-Murcia, María Rosario Pac-Sa, Alejandro Orrico-Sanchéz, Lorna Gómez-Lanas, Diego Sala-Trull, Carmen Domènech-Leon, Alba Del Rio-González, Manuel Sánchez-Urbano and 17 more

Abstract read
In one paragraph

Article in Epidemiologia (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Salvador Domènech-MontoliuEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Joan Puig-BarberàVaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain.ORCID 0000-0001-5783-0409
Olga Guerra-MurciaVaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain.
María Rosario Pac-SaPublic Health Center, 12003 Castelló de la Plana, Spain.
Alejandro Orrico-SanchézVaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, 46020 Valencia, Spain.ORCID 0000-0002-3780-3187
Lorna Gómez-LanasEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Diego Sala-TrullEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Carmen Domènech-LeonUniversidad CEU Cardenal Herrera, 12006 Castelló de la Plana, Spain.
Alba Del Rio-GonzálezHealth Centers I and II, 12530 Borriana, Spain.
Manuel Sánchez-UrbanoEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.ORCID 0000-0002-9629-1601
Paloma Satorres-MartinezEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Marta Latorre-PovedaEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Sara Ferrando-RubertEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Laura Aparisi-EsteveCarinyena Health Center, 12540 Vila-real, Spain.ORCID 0000-0003-4523-652X
Gema Badenes-MarquesEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Roser Blasco-GariEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Juan Casanova-SuarezNursing Service University Hospital de la Plana, 12548 Vila-real, Spain.
María Fontal-CarcelHealth Center, 12600 La Vall d'Uixó, Spain.
María Gil-FortuñoMicrobiology Service University Hospital de la Plana, 12540 Vila-real, Spain.
Noelia Hernández-PérezMicrobiology Service University Hospital de la Plana, 12540 Vila-real, Spain.
David Jovani-SalesEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.ORCID 0000-0002-2378-3445
Laura López-DiagoClinical Analysis Service University Hospital de la Plana, 12540 Vila-real, Spain.
Cristina Notari-RodríguezEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Oscar Pérez-OlasoMicrobiology Service University Hospital de la Plana, 12540 Vila-real, Spain.
María Angeles Romeu-GarciaPublic Health Center, 12003 Castelló de la Plana, Spain.
Raquel Ruíz-PuigEmergency Service University Hospital de la Plana, 12540 Vila-real, Spain.
Alberto Arnedo-PenaPublic Health Center, 12003 Castelló de la Plana, Spain.ORCID 0000-0002-1071-0984

Funding

Vaccines Research Unit, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FI FISABIO-Public Health, 46020 Valencia, Spain.
6 · The paper itself

Abstract

Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6-10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83-1.04), for A-group 1.06 (95% CI 0.94-1.18), for B-group 1.04 (95%CI 0.88-1.24), and for AB-group 1.11 (95% CI 0.81-1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.

Indexed as

ABO blood groupscohort studyCOVID-19incidencemass-gathering eventsSARS-CoV-2

Identifiers

PMID36810454
PMCPMC9944070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.